Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.39 |
| ▸ | PPARG | P37231 | 16/20 | 0.39 |
| ▸ | PPARD | Q03181 | 13/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036127 | 0.92 | PPARA (0.39) | PPARAPPARGPPARD | |
| SCHEMBL6035955 | 0.92 | PPARA (0.42) | PPARAPPARGPPARDACACB | |
| SCHEMBL6035559 | 0.89 | PPARA (0.40) | PPARAPPARGPPARD | |
| SCHEMBL6035156 | 0.87 | PPARA (0.40) | PPARAPPARGPPARD | |
| SCHEMBL6035951 | 0.85 | PPARG (0.35) | PPARAPPARGPPARDACACB | |
| SCHEMBL6036338 | 0.84 | AKR1C3 (0.40) | PPARAPPARGPPARDGCGR | |
| SCHEMBL6035632 | 0.81 | PPARA (0.42) | PPARAPPARGPPARD | |
| SCHEMBL6035532 | 0.80 | HSD17B10 (0.40) | PPARAPPARGPPARD | |
| SCHEMBL6254047 | 0.80 | CYP1A1 (0.38) | PPARAPPARGPPARDACACB | |
| SCHEMBL6036245 | 0.79 | PPARD (0.42) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARA 1717/4885PPARG 1037/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.